XELOX III. Xeloda in Combination With Eloxatin for Patients With Advanced or Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
XELOX (Capecitabine and Oxaliplatin) is an effective and convenient regimen for patients with
metastatic colorectal cancer. Chronomodulated therapy may reduce toxicity. Patients will be
randomized to standard XELOX (Capecitabine 1000 mg/m² in the morning and 1000 mg/m² in the
evening days 1-14 and short term Oxaliplatin 130 mg/m² day 1 in 30 minutes) or
chronomodulated XELOX (Capecitabine 400 mg/m² in the morning and 1600 mg/m² in the evening
days 1-14 and short term Oxaliplatin 130 mg/m² day 1 in 30 minutes).
Bloodsamples will be collected and frozen and later examined for potential predictive factors